CTC Pancreatic Adenocarcinoma

Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells?

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02335151

Enrollment

Registered

2015-01-09

Start date

2016-10-31

Completion date

2019-10-31

Last updated

2019-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma, Circulating Tumor Cells, Pancreatic Neoplasms

Keywords

Circulating Tumor Cells, Anesthesia and immunity, Cell Search System

Brief summary

Proportion of circulating tumor cells (CTC) in the postoperative phase after curative tumor removal of pancreatic cancer will be determined and correlated to the accordance of anesthesia (desflurane versus propofol)

Detailed description

This prospective, randomized study will be conducted over a 36-month period to investigate whether commonly used anesthetics (volatile versus intravenous) have an effect on the changes or occurrence of CTC in patients suffering from primary pancreatic cancer undergoing curative surgery. The specific research question is if there are changes of the CTC count in the postoperative phase in the desflurane group (intervention) compared to the propofol one (control). A secondary question is if these changes can be correlated to tumor outcome.

Interventions

DRUGDesflurane

Apply desflurane as anesthetic

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Age 18 to 85 * ASA I-III ( American Society of Anesthesiologists) * Resectable pancreatic adenocarcinoma * Primary surgery * No neoadjuvant therapy * Written informed consent

Exclusion criteria

* Metastatic disease * Other than primary surgery (recurrence, reconstruction) * Pre-operative chemotherapy * Chronic opioid use * Known hypersensitivity or suspected allergy to propofol, soya or egg proteins * Known hypersensitivity to volatile anaesthetics (malignant hyperthermia) * Pregnancy * Breast feeding * Enrolment in any other clinical trial during the course of this trial, 30 days prior to its beginning or 30 days after its completion

Design outcomes

Primary

Measure	Time frame	Description
Peak of CTC in the postoperative phase after curative tumor removal	Day 0 to Day 7	CTC will be counted and peak of CTC will be determined.

Secondary

Measure	Time frame	Description
Kinetics of CTC after surgery up to day 7	1 year	CTC will be counted and kinetics of CTC will be determined.
Month to Tumor recurrence	1 year	Tumor recurrence will be monitored.
Number of surviving patients	1 year	One year after surgery the number of patients still being alive will be determined.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026